Clinical trials: Cholangiocarcinoma Cancer
Cholangiocarcinoma
The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma
(1) Primary efficacy endpoint: Objective Response Rate (ORR) after 2 treatment cycles. ORR is defined as the proportion of subjects with complete response (CR) and partial response (PR) among all subjects.
- Trial name
- NCT07514533
- Testing
- Vibecototamab（iv）+Putilimab（iv）
- Volunteers
- 60 people
- Sponsor
- Sir Run Run Shaw Hospital
Cholangiocarcinoma, Gallbladder Carcinoma
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with malignant hilar biliary obstruction who are treated by unilateral or bilateral stenting.
- Conditions
- Cholangiocarcinoma, Gallbladder Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02649712
- Testing
- biliary stent
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Xuzhou Central Hospital
Gastrointestinal Cancer, Colorectal Cancer
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
- Conditions
- Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer
- Trial name
- NCT04077372
- Testing
- Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Bladder Cancer, Pancreas Cancer
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
This multicenter, non-randomized, Phase II study will assess the efficacy, safety, and pharmacokinetics of trastuzumab emtansine in participants with HER2 overexpressing locally advanced (unresectable and not treatable with…
- Conditions
- Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
- Trial name
- KAMELEON (NCT02999672)
- Testing
- Trastuzumab Emtansine
- Where
- 16 sites in Italy, Netherlands and 2 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer, Gallbladder Cancer
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer
- Trial name
- ABC06 (NCT01926236)
- Testing
- Active Symptom Control, L-folinic acid, 5 FU
- Where
- 17 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- The Christie NHS Foundation Trust
Intrahepatic Cholangiocarcinoma
HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC
Intrahepatic cholangiocarcinoma (ICC) has an increasing global incidence, and over 70% of patients are diagnosed at unresectable stages with limited survival benefits from standard first-line chemotherapy regimens.
- Trial name
- NCT07841574
- Testing
- hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Lianghe Lu
Choledocholithiasis, Bile Duct Cancer
Loop-tipped Guidewire in Selective Biliary Cannulation
1. Background Advanced guidewires with a U-shaped tip could effectively cross the long or multi-occlusive segment smoothly and go into the distal outflow vessel.
- Conditions
- Choledocholithiasis, Bile Duct Cancer, Pancreatic Cancer, Ampullary Tumor
- Trial name
- NCT02028845
- Testing
- Biliary cannulation with loop guidewire, Biliary cannulation with straight guidewire
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Ajou University School of Medicine
Cholangiocarcinoma, Biliary Stricture
Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic .
Primary Objective: To assess the diagnostic accuracy of cholangioscopy-based assessment using SpyDS technology compared to cholangiography-based assessment using ERCP-guided biopsy and brushing in patients with indeterminate…
- Trial name
- Cholangioscopy (NCT03140007)
- Testing
- single operator cholangioscopy, ERCP guided brushing and biopsy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Asian Institute of Gastroenterology, India
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Cholangiocarcinoma, Intrahepatic
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
We aim to explore the effects and safety of the two cohorts of toripalimab combined with lenvatinib or gemox combined with lenvatinib as first-line therapy in advanced or unresectable intrahepatic cholangiocarcinoma
- Trial name
- NCT04361331
- Testing
- Lenvatinib combined with gemox, Toripalimab combined with lenvatinib
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Hepatoma
Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
It has been shown that patients who undergo liver resection surgery are at high risk for postoperative acute kidney injury (AKI). Sevoflurane may increase the risk for postoperative AKI because of production of compound-A.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Cholangiocarcinoma, Gallbladder Neoplasms
- Trial name
- NCT02174575
- Testing
- Sevoflurane, Desflurane
- Where
- Japan
- Sponsor
- Tokyo Medical and Dental University
Klatskin's Tumor
Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction
Photodynamic therapy (PDT) is a palliative treatment for malignant biliary obstruction. The aim of this study is to assess the feasibility and safety of this technique in the context of a nationwide retrospective analysis.
- Trial name
- NCT02504957
- Testing
- Photodynamic therapy using polyhematoporphyrin
- Volunteers
- 88 people
- Sponsor
- Medical University of Vienna
Intrahepatic Cholangiocarcinoma
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment).
- Trial name
- NCT05328167
- Testing
- Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Jefferson University
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
- Trial name
- NCT04762602
- Testing
- HMPL-306
- Where
- 11 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Hutchmed
Biliary Tract Cancers (BTC)
Cosiporfin Sodium for Injection Photodynamic Therapy
Study Design: Multicenter, open-label, Single Group Study Population: Patients with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma who are inoperable or unwilling to undergo surgery.
- Trial name
- DVDMS (NCT07398339)
- Testing
- Cosiporfin Sodium for injection, DVDMS, Gemcitabine Hydrochloride for Injection, Cisplatin for injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Guangsheng Biopharmaceutical Co., Ltd
Cholangiocarcinoma
Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma
The aim of this study is to investigate the efficacy of photodynamic therapy (PDT) in increasing the survival time, decreasing cholestasis and improving health-related quality of life (HRQoL) by comparing PDT puls stents versus…
- Trial name
- NCT02585856
- Testing
- PDT, stent
- Where
- China
- Volunteers
- 39 people
- Sponsor
- First People's Hospital of Hangzhou
Cholangiocarcinoma, Biliary Tract Cancer
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
The goal of this clinical trial is to learn whether adebrelimab combined with S-1 works as an adjuvant treatment for patients with cholangiocarcinoma after curative surgery. It will also learn about the safety of this treatment.
- Trial name
- NCT07561775
- Testing
- Adebrelimab, S-1
- Volunteers
- 40 people
- Sponsor
- Xingjun Guo
Advanced Solid Tumor, Metastatic Solid Tumor
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Lung Cancer, Colorectal Cancer
- Trial name
- NCT05872867
- Testing
- WM-A1-3389, Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Wellmarker Bio
Liver Cancer
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma
In this study the investigators will be studying the effects of proton beam radiation therapy. This is a very accurate kind of treatment that has been shown to affect less normal tissue than a photon radiation beam.
- Trial name
- NCT00976898
- Testing
- Proton Beam Irradiation
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.